Akorn reports hike in quarterly revenue

BUFFALO GROVE - Akorn Inc., a specialty pharmaceutical company, Tuesday reported total revenue for the first quarter was $22 million, versus $14.5 million in the first quarter 2008, representing an increase of approximately 52 percent.

The revenue increase was driven by higher Td Vaccine sales, which totaled $10.7 million.

The company's net loss was approximately $10.7 million in the first quarter 2009 as compared to $5.5 million in the first quarter 2008. This reflects a higher gross profit that was offset by nonrecurring expenses.

Akorn Inc. manufactures and markets sterile specialty pharmaceuticals.